Compare Quest Diagnostics Inc (DGX) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs MasterCard Inc — how do they compare? Quest Diagnostics Inc trades at $230.93 (market cap $25.48B), while MasterCard Inc trades at $586.71 (market cap $503.50B). The key difference: MasterCard Inc is far larger — about 19.8× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and MasterCard Inc for 134 Days on average.
| DGX | MA | |
|---|---|---|
Market Cap | $25.48B | $503.50B |
Volume | 941,866 | 3,390,859 |
Sector | Health | Financials |
52-Week High | $247.45 | $599.86 |
52-Week Low | $173.49 | $471.55 |
Typical Hold Time | 56 Days | 134 Days |
Enterprise Value | $31.23B | $516.53B |
Dividend Yield | 1.49% | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Mastercard (MA) trades at $585.52, up 2.71% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 2025 revenue of $32.79B, net income margin of 46.34%, and impressive ROE of 241.49%. Recent institutional buying activity and positive analyst sentiment (80% buy ratings) support the stock's momentum as it approaches key resistance levels.
Mastercard presents a compelling growth opportunity with expanding digital payment adoption and strong financial performance, though elevated valuation multiples (P/E 31.6, P/S 14.7) and emerging payment technology competition warrant monitoring. The consensus price target of $666.67 suggests 14% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
